Efficacy and safety of genotype-guided antiplatelet therapy versus standard treatment in 4,604 patients with CAD after PCI: a meta-analysis of randomized controlled trials.

To compare the efficacy and safety of genotype-guided antiplatelet strategy and standard treatment in patient with coronary artery disease (CAD) after percutaneous coronary intervention (PCI). Relevant studies published in Medline, Embase, CoChrane Library were searched for randomized controlled trials (RCTs) until August 2020. Studies were screened by selection criteria, quality assessed using the Cochrane Collaboration's tool. Data were extracted from the included studies and statistically analyzed by RevMan 5.3 software. Four RCTs involving 4,604 patients were included in this meta-analysis. Compared with the standard treatment group, the pooled results showed that genotype-guided group associated with lower risk of major adverse cardiovascular events (MACE, OR=0.52, 95%CI:0.35-0.78, =0.001), any bleeding (OR=0.77, 95%CI: 0.62-0.95, =0.02) and myocardial infarction (MI, OR=0.48, 95%CI:0.33-0.68, <0.0001). There was no significant difference in death of any cause (OR=0.53, 95%CI: 0.18-1.54, =0.25), cardiovascular death (OR=0.74, 95%CI:0.48-1.14, =0.17), target vessel revascularization (OR=0.66, 95%CI:0.39-1.12, =0.12) and major bleeding events (OR=0.86, 95%CI: 0.58-1.28, =0.47). Genotype guided antiplatelet therapy could reduce the risk of MACE, MI and any bleeding events in patients with CAD undergone PCI, compared with standard treatment. Therefore, the findings support that implementation of genotype testing to tailor antiplatelet therapy after PCI.